Clinical trials: THC
Healthy Volunteers
Safety and Pharmacokinetics of Smoked Cannabis in Healthy Patients
No actual human data for pharmacokinetics, metabolism, safety, pharmacodynamics, nor efficacy parameters are available for inhaled medical cannabis.
- Trial name
- NCT04314804
- Testing
- PPP001
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Tetra Bio-Pharma
Alzheimer Disease, Agitation,Psychomotor
Clinical Trial on Agitation in Alzheimer's Dementia
The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from…
- Conditions
- Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS
- Trial name
- CALMA (NCT05543681)
- Testing
- IGC-AD1-Active
- Where
- 28 sites in United States, Canada and 1 more
- Volunteers
- 164 people
- Sponsor
- IGC Pharma, LLC
Multiple Sclerosis, Diabetes
An Observational Post-Marketing Safety Registry of Sativex®
The purpose of this registry is to monitor safety outcomes of patients who are receiving Sativex® for Multiple Sclerosis (MS) spasticity and for off-label indications in the United Kingdom (UK), Germany and Sweden.
- Conditions
- Multiple Sclerosis, Diabetes, Cancer, Neuropathic Pain
- Trial name
- NCT02073474
- Testing
- Sativex®
- Volunteers
- 978 people
- Sponsor
- Jazz Pharmaceuticals
Acute Cannabinoid Intoxication
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test
The aim of this study is to investigate whether ANEB-001 effectively penetrates the brain and inhibits the psychotropic effects of Δ9-Tetrahydrocannabinol (THC), the main psychoactive constituent of cannabis.
- Trial name
- NCT05282797
- Testing
- ANEB-001
- Where
- Netherlands
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Anebulo Pharmaceuticals
Cancer
Comparison of Delta-8-THC to Ondansetron in the Prevention of Acute Nausea From Moderately Emetogenic Chemotherapy
Patients will be treated for 2 consecutive chemo cycles with the study drug for one and placebo for the other. In addition, patients will receive an injection before the chemo, either ondansetron (if receiving placebo inhalation)…
- Trial name
- NCT00285051
- Testing
- inhaled delta-8-THC 300mcg or 600mcg per dose
- Where
- 2 sites in Israel
- Volunteers
- 6 people
- Sponsor
- Rafa Laboratories
ADHD, Hyperactivity
Treatment With Cannabis Oil Containing CBD, THC, CBDV or CBG vs. Placebo of Persons With ADHD
ADHD is the most frequent neuro-developmental disorder in childhood and often continues into adolescence and adulthood. Indicated drug treatments for ADHD fall into 2 categories: stimulants (such as methylphenidate and…
- Conditions
- ADHD, Hyperactivity, Attention Deficit
- Trial name
- NCT05219370
- Testing
- Cannabis oil
- Where
- Israel
- Volunteers
- 8 people
- Sponsor
- Brlev Agricultural Crops Ltd
Pain, Pain Syndrome
Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy
Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates…
- Conditions
- Pain, Pain Syndrome, Pain, Chronic, Chronic Pain
- Trial name
- NCT06072573
- Testing
- Adezunap (AP707)
- Where
- Germany
- Volunteers
- 558 people
- Sponsor
- Apurano Pharmaceuticals GmbH
Attention Deficit Hyperactivity Disorder (ADHD)
The Safety and Efficacy of Terpene-enriched Cannabidiol (CBD) Oil in ADHD
ADHD is the most frequent neurodevelopmental disorder in childhood. Symptoms often appear in preschool years, and most children (65-80%) continue to experience some ADHD-associated symptoms into adolescence and adulthood.
- Trial name
- NCT06542445
- Testing
- Oral CBD oil enriched with terpenes
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Bazelet Nehushtan LtD.
Multiple Sclerosis
An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients
A study to compare the efficacy of GW-1000-02 [named Sativex® in Canada and also named Sativex® Oromucosal Spray] with placebo in relieving five key symptoms of Multiple Sclerosis after six weeks of therapy.
- Trial name
- NCT01610700
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 160 people
- Sponsor
- Jazz Pharmaceuticals
Anxiety, Generalized Anxiety Disorder
Evaluation of Effects of CBD Products on Anxiety Among U.S. Women
The investigators will conduct a retrospective cohort analysis of a consumer trial conducted by Rae Wellness. The trial took place between October 15, 2020 and December 30, 2020 and involved 1350 U.S.
- Trial name
- NCT05108220
- Testing
- Cannabidiol (CBD)- containing consumer products
- Where
- United States
- Volunteers
- 1,350 people, healthy volunteers welcome
- Sponsor
- Radicle Science
Pain, Pain Syndrome
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy
Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates…
- Conditions
- Pain, Pain Syndrome, Pain, Chronic, Chronic Pain
- Trial name
- NCT06071975
- Testing
- Adezunap (AP707)
- Where
- Germany
- Volunteers
- 558 people
- Sponsor
- Apurano Pharmaceuticals GmbH
To Determine Bioequivalence Under Fasting Conditions
Bioavailability Study of Dronabinol Capsules 10 mg Under Fasting Conditions
The purpose of this study is to compare the rate and extent of absorption of Dronabinol 10 mg capsules verses Marinol.
- Trial name
- NCT01380457
- Testing
- Dronabinol, Marinol
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Par Pharmaceutical, Inc.
Pain, Pain Syndrome
Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates…
- Conditions
- Pain, Pain Syndrome, Pain, Chronic, Chronic Pain
- Trial name
- NCT06071949
- Testing
- Adezunap
- Where
- Germany
- Volunteers
- 558 people
- Sponsor
- Apurano Pharmaceuticals GmbH
Chronic Pain
Dronabinol Opioid Sparing Evaluation (DOSE) Trial
This study will be a 12-week, open-label trial that is designed to evaluate the Opioid-Sparing effect of Dronabinol at ranging doses when coadministered with the opioid analgesics that are currently being prescribed to patients…
- Trial name
- NCT03766269
- Testing
- Dronabinol
- Where
- United States
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Daisy Pharma Opioid Venture, LLC
Chronic Pain, Neck Pain
A Study of Cybis™ 10:25 THC:CBD Oil in Adults With Chronic Back/Neck Pain
This is a non-randomised, single arm, open-label study of medical cannabis, Cybis™ 10:25, in participants with chronic back or neck pain in which participants receive escalating doses of Cybis™ 10:25.
- Conditions
- Chronic Pain, Neck Pain, Back Pain, Pain
- Trial name
- CYDEPS (NCT04976738)
- Testing
- Cybis™ 10:25 THC:CBD oil
- Where
- 2 sites in Australia
- Volunteers
- 28 people
- Sponsor
- Cymra Life Sciences
Pharmacokinetic, Tolerability
Clinical Trial on Pharmacokinetic and Tolerability of AP701
This study aims to investigate the uptake of AP701, a preparation from cannabis flowers, into the bloodstream after in single administration in healthy volunteers.
- Conditions
- Pharmacokinetic, Tolerability, Safety
- Trial name
- NCT04708795
- Testing
- AP701
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- CannaXan GmbH
Pain, Pain Syndrome
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy
Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates…
- Conditions
- Pain, Pain Syndrome, Pain, Chronic, Chronic Pain
- Trial name
- NCT06071988
- Testing
- Adezunap (AP707)
- Where
- Germany
- Volunteers
- 558 people
- Sponsor
- Apurano Pharmaceuticals GmbH
Osteoarthritis, Knee, Pain
Osteoarthritis of the Knee Pain Study Using a CBD and THC Sublingual Tablet
This study is a prospective Phase 2, drug controlled, open-label study to evaluate the safety and efficacy of Pure Green sublingual tablets for the treatment of pain associated with osteoarthritis of the knee.
- Trial name
- NCT04195269
- Testing
- Test Article
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Pure Green
Pain, Pain Syndrome
Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain
Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates…
- Conditions
- Pain, Pain Syndrome, Pain, Chronic, Chronic Pain
- Trial name
- NCT06072560
- Testing
- Adezunap (AP707)
- Where
- Germany
- Volunteers
- 558 people
- Sponsor
- Apurano Pharmaceuticals GmbH
Immunologic Deficiency Syndrome, Agammaglobulinemia
Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients
The objective of this study is to determine if the safety and tolerability of Immune Globulin Intravenous (Human), 10% caprylate/chromatography (IGIV-C)purified is similar when infused at two different infusion rates.
- Conditions
- Immunologic Deficiency Syndrome, Agammaglobulinemia, Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome
- Trial name
- NCT00220766
- Testing
- Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified, Dextrose, 5% in Water
- Where
- 13 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Grifols Therapeutics LLC